Urticaria and Angioedema

Urticaria and angioedema are common, often distressing conditions that you will encounter frequently in both general practice and dermatology. Understanding their pathogenesis is not just academic; it directly informs a logical, stepwise approach to management that can dramatically improve patient quality of life.

Pathogenesis: The Mast Cell as the Central Player

At the heart of both urticaria and angioedema is the mast cell, a key effector cell of the immune system. The clinical manifestations are the direct result of mast cell degranulation. When activated, mast cells release pre-formed and newly synthesized mediators from their granules into the surrounding tissues. The most significant of these is histamine.

Histamine binding to H1-receptors on local blood vessels causes vasodilation and increased vascular permeability. This leads to plasma leakage into the dermis, which presents as a wheal—the raised, erythematous, and pruritic (itchy) plaque characteristic of urticaria. When this process occurs in the deeper dermis and subcutaneous or submucosal tissues, the swelling is termed angioedema, which often involves the lips, eyelids, and sometimes the tongue or airways. While pruritus dominates urticaria, angioedema is more often described as a sensation of burning, tightness, or pain.

Differentiating Acute and Chronic Urticaria

The primary distinction in clinical management hinges on duration. Acute urticaria is defined by the sudden appearance of wheals and/or angioedema that persists for less than six weeks. It is extremely common, often triggered by specific, identifiable factors such as infections (particularly viral URI in children), medications (e.g., antibiotics, NSAIDs), certain foods, or insect stings. The hallmark is its self-limited nature; many cases resolve spontaneously with or without minimal treatment once the trigger is removed or the underlying infection clears.

In contrast, chronic urticaria is defined by the presence of symptoms on most days of the week for a period exceeding six weeks. This condition requires a more systematic evaluation. Chronic urticaria is further categorized. Chronic spontaneous urticaria (CSU) has no identifiable external trigger—symptoms appear spontaneously. Chronic inducible urticaria is provoked by a specific physical stimulus like pressure, cold, heat, or vibration. The workup for chronic urticaria focuses on ruling out underlying systemic conditions (like thyroid disease or chronic infections) that may be contributing, though in most cases of CSU, no specific cause is found, and it is considered an autoimmune or autoreactive process.

First-Line Treatment: The Central Role of Antihistamines

For both acute and chronic urticaria, the cornerstone of symptomatic relief is H1-antihistamines. The modern standard of care mandates the use of second-generation antihistamines (e.g., cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine) as first-line therapy. These are preferred over first-generation agents (e.g., diphenhydramine) because they are far less sedating, have longer durations of action, and do not cross the blood-brain barrier as readily, minimizing cognitive side effects.

The treatment approach is stepwise. Patients are started on a standard dose (e.g., cetirizine 10 mg daily). If control is inadequate after 1-2 weeks, the dose should be escalated. Guidelines support increasing the dose up to fourfold the standard dose (e.g., cetirizine up to 40 mg daily) for chronic spontaneous urticaria. This escalation is safe and effective for many patients, as the dose-response curve for these medications in urticaria is often not flat at conventional doses. It is critical to educate patients that these medications are for control of symptoms and must be taken regularly, not just "as needed" during flare-ups, for chronic disease.

Advanced Therapies for Refractory Cases

When high-dose second-generation antihistamines fail to control chronic spontaneous urticaria, the next biologic step is to consider omalizumab. This is a monoclonal antibody that targets and binds to free IgE, the immunoglobulin that typically sits on the surface of mast cells and basophils to trigger degranulation. By sequestering IgE, omalizumab downregulates the expression of the high-affinity IgE receptor (FcεRI) on mast cells, making them less reactive. It is administered as a subcutaneous injection every 4 weeks and is highly effective for a majority of patients with antihistamine-refractory chronic spontaneous urticaria.

For patients who do not respond to omalizumab, other immunomodulators like cyclosporine may be used under specialist supervision. It is important to remember that short courses of systemic corticosteroids (e.g., prednisone) can be used for severe acute exacerbations but are not appropriate for long-term management of chronic urticaria due to their significant side-effect profile.

Common Pitfalls

1. Over-reliance on First-Generation Antihistamines: Prescribing sedating antihistamines like diphenhydramine for chronic daily use impairs quality of life and cognitive function. Always start with a modern second-generation agent.
2. Inadequate Dosing or Duration: Telling a patient with chronic urticaria to take an antihistamine "only when itchy" leads to poor control. Emphasize daily, scheduled dosing and be willing to escalate the dose before declaring treatment failure.
3. Excessive and Unnecessary Testing in Acute Urticaria: Ordering broad allergy panels or autoimmune workups for a simple case of acute urticaria that will likely resolve is not cost-effective. A thorough history is the most valuable diagnostic tool.
4. Missing the Difference Between Angioedema Types: Not all angioedema is histaminergic. Failing to recognize hereditary angioedema (HAE), which involves bradykinin and does not respond to antihistamines or epinephrine, can be dangerous. Clues to HAE include lack of urticaria, involvement of the gastrointestinal tract causing severe abdominal pain, and a positive family history.

Summary

• Urticaria (wheals) and angioedema (deep swelling) are caused by mast cell degranulation and the release of histamine.
• Acute urticaria (<6 weeks) often has an identifiable trigger and may resolve spontaneously, while chronic urticaria (>6 weeks) requires systematic evaluation and long-term management.
• Second-generation, non-sedating H1-antihistamines are the first-line treatment for all forms; doses should be escalated up to fourfold if standard doses are ineffective.
• For patients with antihistamine-refractory chronic spontaneous urticaria, the biologic agent omalizumab, which targets IgE, is a highly effective next-line therapy.
• Always distinguish between histamine-driven angioedema (which accompanies urticaria) and bradykinin-mediated angioedema (e.g., hereditary angioedema), as their treatments differ drastically.